Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer

NCT01438112 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

22

Enrollment

INDUSTRY

Sponsor class

Stopped Change in study design

Conditions

Transitional Cell Carcinoma
Bladder Cancer
Carcinoma in Situ
Carcinoma in Situ Concurrent With Papillary Tumors

Interventions

BIOLOGICAL: CG0070 Adenovirus Vector
OTHER: Control Arm: Quadruple Choice

Sponsor

CG Oncology, Inc.